The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Stereotactic radiosurgery (SRS) for non-small cell lung cancer (NSCLC) in the oncogene-addicted era: A real-world UK tertiary center experience.
 
David Mcmahon
Consulting or Advisory Role - Pfizer
Travel, Accommodations, Expenses - Pfizer; Takeda
 
James De Boisanger
No Relationships to Disclose
 
Alexius John
No Relationships to Disclose
 
Martin Brewer
No Relationships to Disclose
 
Elizabeth Cartwright
No Relationships to Disclose
 
Thubeena Manickavasagar
No Relationships to Disclose
 
Charlotte Milner-Watts
No Relationships to Disclose
 
Liam Welsh
No Relationships to Disclose
 
Antonia Creak
No Relationships to Disclose
 
Nadia Yousaf
No Relationships to Disclose
 
Michael Davidson
Speakers' Bureau - Takeda
 
Jaishree Bhosle
No Relationships to Disclose
 
Anna Rachel Minchom
Honoraria - GlaxoSmithKline; Janssen; Merck; Seagen
Consulting or Advisory Role - Faron Pharmaceuticals; GlaxoSmithKline; Janssen Oncology; MSD
Research Funding - Astex Pharmaceuticals (Inst); Merck (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Mary E.R. O'Brien
Employment - Oxford Biomedica (I)
Honoraria - Abbvie; Bristol-Myers Squibb; Merck; Merck; Merck Serono
Consulting or Advisory Role - Amgen; Eisai Europe; ITeos Therapeutics; Merck; Merck; PharmaMar; PharmaMar; Pierre Fabre; Puma Biotechnology
Patents, Royalties, Other Intellectual Property - Book: Fast fact NSCLC edition 1 and 2, published by Karger (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Sanjay Popat
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Guardant Health; Janssen; Lilly; Merck KGaA; Novocure; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; EQRx; GlaxoSmithKline; Guardant Health; IO Biotech; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell (Inst); Turning Point Therapeutics (Inst)
 
Francesca Solda
No Relationships to Disclose
 
Helen Taylor
No Relationships to Disclose
 
Jessica Konadu
No Relationships to Disclose
 
Nadza Tokaca
No Relationships to Disclose
 
Nicola Rosenfelder
No Relationships to Disclose